CA3008084A1 - Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof - Google Patents

Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof Download PDF

Info

Publication number
CA3008084A1
CA3008084A1 CA3008084A CA3008084A CA3008084A1 CA 3008084 A1 CA3008084 A1 CA 3008084A1 CA 3008084 A CA3008084 A CA 3008084A CA 3008084 A CA3008084 A CA 3008084A CA 3008084 A1 CA3008084 A1 CA 3008084A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutical composition
precipitate
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3008084A
Other languages
English (en)
French (fr)
Inventor
Stig Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of CA3008084A1 publication Critical patent/CA3008084A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
CA3008084A 2015-12-18 2016-12-10 Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof Pending CA3008084A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1500520 2015-12-18
SE1500520-0 2015-12-18
PCT/EP2016/025175 WO2017102097A1 (en) 2015-12-18 2016-12-10 Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof

Publications (1)

Publication Number Publication Date
CA3008084A1 true CA3008084A1 (en) 2017-06-22

Family

ID=58231562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3008084A Pending CA3008084A1 (en) 2015-12-18 2016-12-10 Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof

Country Status (14)

Country Link
US (1) US10668056B2 (enExample)
EP (1) EP3390403B1 (enExample)
JP (2) JP6929299B2 (enExample)
CN (1) CN108431003A (enExample)
AU (1) AU2016371541B2 (enExample)
CA (1) CA3008084A1 (enExample)
DK (1) DK3390403T3 (enExample)
EA (1) EA039778B1 (enExample)
ES (1) ES2925690T3 (enExample)
HK (1) HK1257129A1 (enExample)
HU (1) HUE059610T2 (enExample)
PL (1) PL3390403T3 (enExample)
PT (1) PT3390403T (enExample)
WO (1) WO2017102097A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3390403T (pt) * 2015-12-18 2022-09-06 Vivolux Ab Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos
WO2021044608A1 (ja) * 2019-09-06 2021-03-11 シミックホールディングス株式会社 ダントロレン水性製剤及びその調製方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US20060217437A1 (en) * 2005-03-17 2006-09-28 Burmester James K TGF-beta modulators and methods for using the same
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
ES2681703T3 (es) * 2011-03-21 2018-09-14 Vivolux Ab Tratamiento de tumores sólidos
EP2900667B1 (en) * 2012-09-21 2019-06-05 Vivolux AB Means and method for treating solid tumours
PT3390403T (pt) * 2015-12-18 2022-09-06 Vivolux Ab Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos

Also Published As

Publication number Publication date
PT3390403T (pt) 2022-09-06
WO2017102097A1 (en) 2017-06-22
AU2016371541A1 (en) 2018-06-07
EP3390403A1 (en) 2018-10-24
EP3390403B1 (en) 2022-06-29
US10668056B2 (en) 2020-06-02
ES2925690T3 (es) 2022-10-19
HUE059610T2 (hu) 2022-12-28
US20180280366A1 (en) 2018-10-04
JP6929299B2 (ja) 2021-09-01
CN108431003A (zh) 2018-08-21
JP2019505571A (ja) 2019-02-28
PL3390403T3 (pl) 2022-10-24
DK3390403T3 (da) 2022-08-29
HK1257129A1 (zh) 2019-10-11
JP2021130673A (ja) 2021-09-09
EA201891027A1 (ru) 2019-02-28
EA039778B1 (ru) 2022-03-14
AU2016371541B2 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
ES2969901T3 (es) Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores
CN109563100B (zh) 三唑并嘧啶化合物的晶体形式
KR102342776B1 (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
JP7853221B2 (ja) ４－アミノ－５－（６－（４－メチルピペラジン－１－イル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－イル）チエノ［２，３－ｂ］ピリジン－６（７ｈ）－オンの塩及び結晶形
AU2014295144B2 (en) Salts of Dasatinib in crystalline form
KR20070073864A (ko) 증식성 질환의 치료를 위한 ｓｒｃ 키나제 억제제 및ｂｃｒ-ａｂｌ 억제제의 조합물
EP4403225A2 (en) Substituted imidazoquinolines
AU2016371541B2 (en) Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof
BR112020004505A2 (pt) imidazoquinolinas substituídas como agonistas de tlr7
EP2900667A1 (en) Means and method for treating solid tumours
EP2714683A2 (en) Amorphous ritonavir co-precipitated
EP3368527B1 (en) Palbociclib tosylate
KR20210126629A (ko) 화합물 결정형, 이의 제조 방법, 약물 조성물 및 응용
JP2025527820A (ja) キノリン誘導体阻害剤の結晶形、及びその調製方法並びに用途
WO2024067085A1 (zh) 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
OA16810A (en) N- (3- {[(3- {[2-chloro-5-(methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phenyl) 2 -methylalaninamide as phosphatidylinositol 3 kinase inhibitor for the treatment of lymphoproliferative malignancies.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210914

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240910

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250910

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260121